changes in protein profiles in bortezomib applied multiple myeloma ...

More documents

Recommendations

Info

REFERENCES Aebersold, R. and Mann, M. 2003. Mass spectrometry-based proteomics. Nature 422: 198-207. Abbott, A. 1999. A post-genomic challenge: learning to read patterns of protein synthesis. Nature 402: 715-20. Adams, J. M. 2003. Ways of dying: multiple pathways to apoptosis. Genes & Development 17: 2481–2495. Adams, J. 2003. The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews 29(suppl 1): 3-9. Adams, J. and Kauffman, M. 2004. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investigation 22(2): 304-11. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. and Walter, P. 2008. Molecular Biology of the Cell, 5th edition, New York, Garland Science. ACS, American Cancer Society. http :// www.cancer.org / acs / groups / cid / documents / webcontent / 003121-pdf.pdf (accessed 2011). Alexanian, R., Barlogie, B. and Dixon, D. 1990. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of Internal Medicine 150: 1693–1695. Anand, P., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, O. S., Sung, B. and Aggarwal, B. B. 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research (9): 2097-116. Anderson, K. C. 2003. Multiple Myeloma: How Far Have We Come? Mayo Clinic Proceedings 78: 15-17. Anderson, K. C. 2004. The clinical potential of proteasome inhibition. European Journal of Cancer Supplements 2(6): 3–6. Anderson, L. and Seilhamer, J. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18: 533-7. Avet-Loiseau, H., Facon, T., Grosbois, B., et al. 2002. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly 89
distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99: 2185-2191. Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., Obeid, L. M. and Ogretmen, B. 2007. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. The Journal of Biological Chemistry 282: 10922-10934. Barillé-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J. and Tricot G. 2003. Advances in Biology and Therapy of Multiple Myeloma. American Society of Hematology (ASH) 248-78. Barker, J. 1999. Mass Spectrometry John Wiley & Sons, Chichester, England. Bataille, R., Boccadoro, M., Klein, B., Durie, B. and Pileri, A. 1992. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733–737. Bataille, R. and Harousseau, J. L. (1997). Multiple Myeloma. New England Journal of Medicine 336: 1657-1664. Beavis, R. C. and Chait, B. T. 1989. Cinnamic acid derivatives as matrices for ultraviolet laser desorption mass spectrometry of proteins. Rapid Communication in Mass Spectrometry 3: 432-435. Beavis, R. C., Chaudhary, T. and Chait, B. T. 1992. α-cyano-4-hydroxycinnamic acid as a matrix for matrix-assisted laser desorption mass spectrometry. Organic Mass Spectrometry 27: 156-158. Bendixen, E. 2005. The use of proteomics in meat science. Meat Science 71: 138-149. Berggren, K., Chernokalskaya, E., Steinberg, T. H., Kemper, C., Lopez, M. F., Diwu, Z., Haugland, R. P. and Patton, W. F. 2000. Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfatepolyacrylamide gels using a luminescent ruthenium complex. Electrophoresis 21: 2509-2521. Bergsagel, P. L. and Kuehl, W. M. 2001. Chromosome translocations in multiple myeloma. Oncogene 20(40): 5611-22. Bilir, N. 2008. Sigara ve Kanser. Vol: 1, Klasmat, Ankara, Pp: 7. Blade, J., Cibeira, M. T. and Rosinol, L. 2005. Bortezomib: A Valuable New Antineoplastic Strategy in Multiple Myeloma. Acta Oncologica 44: 440-448. Bommert, K., Bargou, R. C. and Stühmer, T. 2006. Signalling and survival pathways in multiple myeloma. European Journal of Cancer. 4 2: 1574-1580. 90
Page 1 and 2:
CHANGES IN PROTEIN PROFILES IN BORT
Page 3 and 4:
ACKNOWLEDGEMENTS First of all, with
Page 5 and 6:
ÖZET BORTEZOMĠB UYGULANAN MULTĠP
Page 7 and 8:
2.1.4.1.2. Two-Dimensional Gel Elec
Page 9 and 10:
LIST OF FIGURES Figure Page Figure
Page 11 and 12:
LIST OF TABLES Table Page Table 1.1
Page 13 and 14:
When normal cells in the body begin
Page 15 and 16:
Figure 1.2. Development of Cancer S
Page 17 and 18:
the myeloma cells does not help fig
Page 19 and 20:
A rare form of MM called Nonsecreto
Page 21 and 22:
1.2.3. Risk Factors for MM A risk f
Page 23 and 24:
of the mineralizations by adjusting
Page 25 and 26:
To measure the levels of red cells,
Page 27 and 28:
The levels of blood urea nitrogen (
Page 29 and 30:
By using the system introduced by D
Page 31 and 32:
1.2.7.2. Biology of The Proteasome
Page 33 and 34:
Figure 1.10. Ubiquitin-Proteasome P
Page 35 and 36:
Figure 1.12. Effect of Bortezomib o
Page 37 and 38:
encompasses the investigation of pr
Page 39 and 40:
of modification. Ubiquitin is a sma
Page 41 and 42:
the given cells. On the other hand,
Page 43 and 44:
is-acrylamide (N,N'-methylene-bisac
Page 45 and 46:
2.1.4.2. Detection of Protein Spots
Page 47 and 48:
ange of 600-2500 Da. This is the id
Page 49 and 50: ions resolved by the mass analyzer
Page 51 and 52: 2.1.4.5.2. Mass Analyzers Figure 2.
Page 53 and 54: There is no doubt that different ma
Page 55 and 56: mask low-quantity proteins that may
Page 57 and 58: 3.1. Materials 3.1.1. Medias CHAPTE
Page 59 and 60: 3.2.5. Cell Proliferation Assay Ant
Page 61 and 62: After 72 hour incubation period at
Page 63 and 64: eceptors of the Tumor Necrosis Fact
Page 65 and 66: The preparation of stock BSA Standa
Page 67 and 68: 3.2.6.3. Detection of the Loss of M
Page 69 and 70: centrifugation, the supernatant was
Page 71 and 72: selected symmetrically to load the
Page 73 and 74: approximately 35 ml, the volume of
Page 75 and 76: After electrophoresis was finished,
Page 77 and 78: 7 Day Two: Reduction, Alkylation, a
Page 79 and 80: CHAPTER 4 RESULTS AND DISCUSSION 4.
Page 81 and 82: % Changes in Cytoplasmic/Mitochondr
Page 83 and 84: Table 4.1. Magnified Segments of Di
Page 85 and 86: Table 4.1. Magnified Segments of Di
Page 87 and 88: After labeling, black and red color
Page 89 and 90: 78 7 8 Y2S Y3S Table 4.2. Results o
Page 91 and 92: 80 12 S4Ca Table 4.2. Results of Di
Page 93 and 94: 82 27 Y5S Table 4.2. Results of Dif
Page 95 and 96: Spot 4, Ubiquitin-conjugating enzym
Page 97 and 98: is a transcriptional repressor, but
Page 99: activity and loss of mitochondrial
Page 103 and 104: DeMartino, G. N. and Slaughter, C.
Page 105 and 106: proteomic analyses of a systematica
Page 107 and 108: Mahindraa, A., Hideshimab, T. and A
Page 109 and 110: Richardson, P. G., Hideshima, T. an
Page 111 and 112: Terpos, E. 2008. Bortezomib Directl
Page 113 and 114: A.1. RPMI-1640 Growth Medium APPEND
Page 115 and 116: Table B.1. Chemicals and Reagents U
Page 117 and 118: B.4.3. Standard Curve for BSA Table
Page 119 and 120: Urea (8M) 4.8 g CHAPS (%2) 0.2 g DT
Page 121 and 122: E. F. G. STOCK REAGENT PREPARATION
show all

changes in protein profiles in bortezomib applied multiple myeloma ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?